Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Reproductive Health Informed Consent topic
No spam. Unsubscribe anytime.
House approves HB141 adding informed‑consent language about medication abortion after extended debate
Summary
The House passed second substitute HB141, which adds informed‑consent language about medication abortion (noting mifepristone alone may not always end a pregnancy); the measure passed 56–13 following lengthy debate over medical evidence and limits of legislative prescription.
SALT LAKE CITY — After an extended and often emotional floor debate, the Utah House passed second substitute House Bill 141 on Feb. 24. The bill, described by the sponsor as an informed‑consent measure, requires that certain written information include language noting that mifepristone alone may not always be effective in ending a pregnancy. The final roll call recorded 56 Yeas and 13 Nays.
Representative Stratton, the bill sponsor, said the language is intended to ensure that ‘‘a choice is well informed’’ and that the wording in part comes from stakeholder groups, including the American Congress of Obstetricians and Gynecologists and civil‑liberties organizations, according to his floor remarks. In explaining the provision, Stratton said: "Research indicates that mifepristone alone is not always effective in ending a pregnancy. You may still have a viable pregnancy after taking mifepristone." He urged colleagues to view the bill as an informed‑consent measure rather than a new clinical protocol.
Opponents, including Representative Brian King, challenged the scientific foundation of the language and cautioned against the legislature prescribing medical detail. King said the evidence cited was limited and warned the chamber against ‘‘injecting ourselves between a woman and her doctor.’’ He described the small size and limited reliability of studies the bill references, saying they amounted to ‘‘an experiment’’ and were not sufficient to form the basis of policy.
Other members raised constitutional and free‑speech concerns, with supporters countering that the bill was developed in consultation with physicians and professional associations. Several members asked whether the language forces physicians to make statements contrary to their own medical judgment; sponsors said the bill focuses on information that should be available to patients and does not prescribe clinical practice.
On the floor, members also debated terminology and tone; Representative Brian King urged colleagues to use clinical terms such as "zygote" and "embryo" rather than language like "baby" in policy debate. Representative Stratton emphasized respect for divergent views and said the bill was not intended as an anti‑choice or pro‑choice measure but as an informational tool.
The bill passed and will be sent to the Senate for further consideration.
